For the narrow job of raising blood NAD⁺ they look interchangeable — a 2026 randomized trial testing both head to head found NMN and NR raised circulating NAD⁺ comparably. Neither has shown a proven health benefit in healthy people, and a 2025 meta-analysis found neither preserves muscle in older adults. Magellan stocks NMN and does not stock NR; that is a supply fact, not a verdict.
| Compared on | NMN | NR |
|---|---|---|
| Evidence grade | Moderate evidence | Not graded here Magellan does not stock an NR product, so it carries no product grade. The evidence below is cited on the same basis as everything else on the site. |
| What it is | Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and a direct biosynthetic precursor of nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular energy metabolism, DNA repair, and the activity of sirtuin and PARP enzymes. | A vitamin B3-derived NAD⁺ precursor. The NMN monograph on this site names it as one of several precursors that human trials also show can raise NAD⁺. |
| Best human evidence | “Insulin-stimulated glucose disposal, assessed by using the hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling [phosphorylation of protein kinase AKT and mechanistic…” Science 2021 · PMID 33888596 | “Nicotinamide riboside (1,000 mg/day for 6 weeks) raised blood NAD+ by about 60% and was well tolerated, with exploratory signals for lower blood pressure and aortic stiffness.” Nature communications 2018 · PMID 29599478 |
| Dose / protocol studied | 250–900 mg/day (600 mg looked optimal in one dose-ranging trial) | 1,000 mg/day for 6 weeks in the Nature Communications crossover trial; the NR + pterostilbene trials used 1,000 mg NR with 200 mg pterostilbene. |
| Typical listed price | $34.95 | Not stocked |
| Who it suits | Someone who wants the most-trialled NAD⁺ precursor and accepts that the endpoint is a blood level, not a health outcome. | Someone who wants the precursor with the least regulatory ambiguity on US shelves and is comfortable buying it elsewhere. |
| Who should skip it | Anyone expecting weight, glucose or lipid changes — several meta-analyses of those endpoints are null. | Anyone buying it for muscle: a 2025 meta-analysis in older adults concluded current evidence does not support NMN or NR for preserving muscle mass and function. |
| Key caveat | Oral NMN reliably raises blood NAD⁺ and has been well tolerated in trials up to about 900–1,250 mg/day. Functional benefits so far are modest and population-specific (muscle insulin sensitivity in prediabetic women, aerobic capacity, walking speed, sleep quality), several meta-analyses are null for glucose, lipids and muscle mass, and no trial shows effects on aging, disease prevention, or lifespan. | The two best NR trials on this page are honest about their limits: the 2018 crossover raised NAD⁺ about 60% but reported no significant improvement in blood pressure or arterial stiffness, and the muscle-injury trial in older adults was flatly negative. |
Prices are the typical listed prices in our catalog, not live Amazon prices, and a true cost-per-studied-dose is not shown because our catalog does not record servings per container — we would have to guess, so we don't.
The two precursors do the same biochemical job. The choice mostly comes down to what you expect from it.
Either — this is the one thing both reliably do. NMN raised blood NAD⁺ at 300, 600 and 900 mg/day in the dose-finding trial with the effect plateauing near 600 mg, and NR raised it about 60% at 1,000 mg/day. The 2026 head-to-head found them comparable.
Neither. The 2025 systematic review and meta-analysis in the Journal of Cachexia, Sarcopenia and Muscle concluded that current evidence does not support NMN or NR supplementation for preserving muscle mass and function in adults averaging over 60.
NMN, with modest expectations. The single most interesting human result for either compound is the 2021 Science trial: NMN increased insulin-stimulated glucose disposal and muscle insulin signalling in prediabetic women. It has not been replicated broadly, and meta-analyses of glucose endpoints overall are null.
NR. Our long-form article records that the FDA has taken the position that NMN cannot be sold as a dietary supplement because it was previously investigated as a drug, which has pushed some retailers to pull or relabel products. That is a regulatory dispute, not a safety verdict.
The mechanism these products target is the same one exercise and dietary restriction act on. Endurance exercise activates the SIRT1–NAD⁺ pathway that NAD⁺ boosters aim at, and fasting and calorie restriction modulate NAD⁺ alongside AMPK and mTOR.
Diet cannot reach trial doses of NMN — edamame, broccoli and avocado supply roughly 0.25–1.9 mg per 100 g — so if you want the blood level, a capsule is the only route. The honest question is whether the blood level is worth anything yet, and on current human evidence the answer is: unproven.
Each quote below is taken verbatim from the cited paper. Null and negative results are included on purpose — they are the reason a grade means anything.
“Insulin-stimulated glucose disposal, assessed by using the hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling [phosphorylation of protein kinase AKT and mechanistic target of rapamycin (mTOR)] increased after NMN supplementation but did not change after placebo treatment.”
“Physical-performance improvements from NMN tracked the rise in blood NAD+, with benefit maximized around 600 mg/day in a dose-dependent trial.”
“There were nominally significant improvements in gait speed and performance in the left grip test, which should be validated in larger studies; however, NMN exerted no significant effect on body composition.”
“Nicotinamide riboside (1,000 mg/day for 6 weeks) raised blood NAD+ by about 60% and was well tolerated, with exploratory signals for lower blood pressure and aortic stiffness.”
“Current evidence does not support NMN and NR supplementation for preserving muscle mass and function in adults with mean age of over 60 years.”
“Daily supplementation with 1,000 mg NR and 200 mg PT is safe but does not improve recruitment of the MuSC pool or other measures of muscle recovery in response to injury or subsequent regeneration in elderly individuals.”
Magellan does not sell this option — which is exactly why we can compare it honestly.
Links go to an Amazon search for the product name, not to a specific listing, so you can compare sellers, price and third-party testing yourself.
For raising blood NAD⁺, no — a 2026 randomized trial testing NMN, NR and plain nicotinamide side by side found NR and NMN raised circulating NAD⁺ to a comparable degree. For health outcomes, neither has convincing evidence in healthy people.
They work at the level they are measured: both reliably raise blood NAD⁺ in randomized trials. Downstream benefits are the unresolved part — several meta-analyses of glucose, lipids and muscle mass are null, and a 2025 meta-analysis specifically found neither precursor preserved muscle in older adults.
Human RCTs used 250–1,200 mg/day, well tolerated up to about 900 mg/day, with one dose-finding trial reporting benefits peaking near 600 mg/day. Most trials ran 6–12 weeks.
Catalog coverage is a stocking decision, not an evidence judgement. We grade NMN Moderate and we have published the null NR trials on this page in full, including the meta-analysis that concludes neither works for muscle.
Different jobs. Urolithin A has the better randomized evidence for aging muscle — endurance and strength…
Neither is a proven senolytic in people. Quercetin has the better human data — meta-analyses show a 2–3 mmHg…
Creatine, unless you cannot train. It is the only compound in this pair graded Strong: meta-analyses of…